Søgeord (influenza) valgt.
477 emner vises.
1
Myndighederne følger udviklingen af fugleinfluenza nøje
Statens Serum Institut, 20.04.2024
Tilføjet 20.04.2024
Fugleinfluenzavirus fundet hos køer i USA har skabt opmærksomhed. Den danske myndighedsgruppe for Koordinering af Zoonoser (KOZO) følger situationen tæt.
Læs mere
2
Weekly respiratory virus update, week 14, April 2024
ECDC
ECDC COVID-19 updates, 15.04.2024
Tilføjet 15.04.2024
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels.
Læs mere
3
Communicable disease threats report, 7 - 13 April 2024, week 15
ECDC
ECDC COVID-19 updates, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mere
4
Communicable disease threats report, 7 - 13 April 2024, week 15
ECDC
ECDC Communicable Disease Threats Report, 12.04.2024
Tilføjet 12.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 7 - 13 April 2024 and includes updates on measles, avian influenza, COVID-19, Mpox, seasonal influenza, RSV, cholera and shigellosis.
Læs mere
5
Excess mortality in Europe coincides with peaks of COVID-19, influenza and respiratory syncytial virus (RSV), November 2023 to February 2024
Sarah K Nørgaard, Jens Nielsen, Anne Christine Nordholm, Lukas Richter, Alena Chalupka, Natalia Bustos Sierra, Toon Braeye, Maria Athanasiadou, Theodore Lytras, Gleb Denissov, Oskari Luomala, Anne Fouillet, Isabelle Pontais, Matthias an der Heiden, Benedikt Zacher, Alina Weigel, Ivo Foppa, Kassiani Gkolfinopoulou, Ioannis Panagoulias, Anna Paldy, Tibor Malnasi, Lisa Domegan, Eva Kelly, Naama Rotem, Oksana Rakhlin, Francesca K de'Donato, Chiara Di Blasi, Patrick Hoffmann, Telma Velez, Kathleen England, Neville Calleja, Liselotte van Asten, Femke Jongenotter, Ana Paula Rodrigues, Susana Silva, Petra Klepac, Diana Gomez-Barroso, Inmaculada Leon Gomez, Ilias Galanis, Ahmed Farah, Rolf Weitkunat, Katarina Fehst, Nick Andrews, Tom Clare, Declan T Bradley, Mark G O'Doherty, Naoma William, Mark Hamilton, Bolette Søborg, Tyra G Krause, Nick Bundle and Lasse S Vestergaard
Eurosurveillance latest updates, 12.04.2024
Tilføjet 12.04.2024
Since the end of November 2023, the European Mortality Monitoring Network (EuroMOMO) has observed excess mortality in Europe. During weeks 48 2023–6 2024, preliminary results show a substantially increased rate of 95.3 (95% CI: 91.7–98.9) excess all-cause deaths per 100,000 person-years for all ages. This excess mortality is seen in adults aged 45 years and older, and coincides with widespread presence of COVID-19, influenza and respiratory syncytial virus (RSV) observed in many European countries during the 2023/24 winter season.
Læs mere
6
CDC Issues Health Alert for Bird Flu Infection in US
Medscape Infectious Diseases, 8.04.2024
Tilføjet 8.04.2024
The U.S. CDC on Friday issued a health alert to inform clinicians, state health departments and the public of a case of avian influenza in a person who had contact with... Reuters Health Information
Læs mere
7
Weekly respiratory virus update, week 13, April 2024
ECDC
ECDC COVID-19 updates, 8.04.2024
Tilføjet 8.04.2024
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels.
Læs mere
8
European Scientists Assess Avian Flu Pandemic Risk
Medscape Infectious Diseases, 6.04.2024
Tilføjet 6.04.2024
The risk for widespread infection for humans from avian influenza remains low in Europe, but health authorities have urged enhanced vigilance and biosecurity measures. Medscape Medical News
Læs mere
9
Communicable disease threats report, 31 March - 6 April 2024, week 14
ECDC
ECDC COVID-19 updates, 5.04.2024
Tilføjet 5.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 March - 6 April 2024 and includes updates on SARS-CoV-2, cholera, avian influenza A(H5N1), swine influenza A(H1N2) and Middle East respiratory syndrome coronavirus (MERS-CoV).
Læs mere
10
Communicable disease threats report, 31 March - 6 April 2024, week 14
ECDC
ECDC Communicable Disease Threats Report, 5.04.2024
Tilføjet 5.04.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 March - 6 April 2024 and includes updates on SARS-CoV-2, cholera, avian influenza A(H5N1), swine influenza A(H1N2) and Middle East respiratory syndrome coronavirus (MERS-CoV).
Læs mere
11
Fugleinfluenzavirus fundet i køer i USA
Statens Serum Institut, 5.04.2024
Tilføjet 5.04.2024
Flere amerikanske malkekvægsbesætninger er testet positive for fugleinfluenzavirus, det er usædvanligt at køer smittes med denne form for virus. Dansk Veterinær Konsortium (DK-VET) følger udviklingen nøje.
Læs mere
12
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mere
13
Digital Nudges Found to Be Duds in Flu Vax Trial
Medscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Reminders sent via text message or patient portal did not increase rates of influenza vaccination. Medscape Medical News
Læs mere
14
Communicable disease threats report, 24-30 March 2024, week 13
ECDC
ECDC Communicable Disease Threats Report, 27.03.2024
Tilføjet 27.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 24-30 March 2024 and includes updates on cholera and influenza A(H5N1).
Læs mere
15
Severe Flu Confers Higher Risk for Neuro Disorders vs COVID
Medscape Infectious Diseases, 22.03.2024
Tilføjet 22.03.2024
Hospitalization for influenza raises the risk for future neurologic conditions more than hospitalization for COVID-19, the results of a large study showed. Medscape Medical News
Læs mere
16
Reporting Protocol for integrated respiratory virus surveillance, version 1.5
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This Reporting Protocol describes data collection for influenza, COVID-19, and other respiratory viruses (such as RSV or new viruses of public health concern) in the EU/EEA and wider WHO European Region. Data collection is integrated for most datasets in line with the operational considerations for respiratory virus surveillance in Europe.
Læs mere
17
Communicable disease threats report, 10-16 March 2024, week 11
ECDC
ECDC COVID-19 updates, 15.03.2024
Tilføjet 15.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
Læs mere
18
Communicable disease threats report, 10-16 March 2024, week 11
ECDC
ECDC Communicable Disease Threats Report, 15.03.2024
Tilføjet 15.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 10-16 March 2024 and includes updates on SARS-CoV-2 variant classification, avian influenza, measles, cholera, and overview of respiratory virus epidemiology in the EU/EE.
Læs mere
19
Communicable disease threats report, 25 February - 2 March 2024, week 9
ECDC
ECDC COVID-19 updates, 2.03.2024
Tilføjet 2.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
20
Communicable disease threats report, 25 February - 2 March 2024, week 9
ECDC
ECDC Communicable Disease Threats Report, 1.03.2024
Tilføjet 1.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 25 February - 2 March 2024, and includes updates on on cholera, avian influenza, SARS-CoV-2 variant classification, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
21
Does an October Birthday Protect Kids From Flu?
Medscape Infectious Diseases, 1.03.2024
Tilføjet 1.03.2024
New research showed that children born in October may have lower rates of influenza diagnosis. Medscape Medical News
Læs mere
22
Effectiveness of interventions to increase healthcare workers’ adherence to vaccination against vaccine-preventable diseases: a systematic review and meta-analysis, 1993 to 2022
Marco Clari, Beatrice Albanesi, Rosanna Irene Comoretto, Alessio Conti, Erika Renzi, Michela Luciani, Davide Ausili, Azzurra Massimi and Valerio Dimonte
Eurosurveillance latest updates, 1.03.2024
Tilføjet 1.03.2024
BackgroundVaccination adherence among healthcare workers (HCWs) is fundamental for the prevention of vaccine-preventable diseases (VPDs) in healthcare. This safeguards HCWs\' well-being, prevents transmission of infections to vulnerable patients and contributes to public health. AimThis systematic review and meta-analysis aimed to describe interventions meant to increase HCWs’ adherence to vaccination and estimate the effectiveness of these interventions. MethodsWe searched literature in eight databases and performed manual searches in relevant journals and the reference lists of retrieved articles. The study population included any HCW with potential occupational exposure to VPDs. We included experimental and quasi-experimental studies presenting interventions aimed at increasing HCWs’ adherence to vaccination against VPDs. The post-intervention vaccination adherence rate was set as the main outcome. We included the effect of interventions in the random-effects and subgroup meta-analyses. ResultsThe systematic review considered 48 studies on influenza and Tdap vaccination from database and manual searches, and 43 were meta-analysed. A statistically significant, positive effect was seen in multi-component interventions in randomised controlled trials (relative risk (RR) = 1.37; 95% CI: 1.13–1.66) and in observational studies (RR = 1.43; 95% CI: 1.29–1.58). Vaccination adherence rate was higher in community care facilities (RR = 1.58; 95% CI: 1.49–1.68) than in hospitals (RR = 1.24; 95% CI: 0.76-2.05). ConclusionInterventions aimed at increasing HCWs’ adherence to vaccination against VPDs are effective, especially multi-component ones. Future research should determine the most effective framework of interventions for each setting, using appropriate study design for their evaluation, and should compare intervention components to understand their contribution to the effectiveness.
Læs mere
23
Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza - California, October 2023-January 2024
Morbidity and Mortality Weekly Report (MMWR), 29.02.2024
Tilføjet 29.02.2024
This report describes estimated vaccine effectiveness for laboratory-confirmed flu in California.
Læs mere
24
Interim Estimates of 2023-24 Seasonal Influenza Vaccine Effectiveness - United States
Morbidity and Mortality Weekly Report (MMWR), 29.02.2024
Tilføjet 29.02.2024
This report describes estimates of 2023-24 influenza vaccine effectiveness among different age groups.
Læs mere
25
Communicable disease threats report, 18-24 February 2024, week 8
ECDC
ECDC COVID-19 updates, 24.02.2024
Tilføjet 24.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
26
Communicable disease threats report, 18-24 February 2024, week 8
ECDC
ECDC Communicable Disease Threats Report, 23.02.2024
Tilføjet 23.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 18-24 February 2024 and includes updates on influenza, poliomyelitis, SARS-CoV-2, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
27
Europe Greenlights Two Avian Flu Vaccines
Medscape Infectious Diseases, 23.02.2024
Tilføjet 23.02.2024
The vaccines, Celldemic and Incellipan, protect against the H5N1 subtype of the influenza A virus. Medscape Medical News
Læs mere
28
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
Hannah Chung, Michael A Campitelli, Sarah A Buchan, Aaron Campigotto, Natasha S Crowcroft, Jonathan B Gubbay, James KH Jung, Timothy Karnauchow, Kevin Katz, Allison J McGeer, J Dayre McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Margaret L Russell, Kevin L Schwartz, Andrew Simor, Marek Smieja, Maria E Sundaram, Bryna F Warshawsky, George Zahariadis, Jeffrey C Kwong and on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWaning immunity from seasonal influenza vaccination can cause suboptimal protection during peak influenza activity. However, vaccine effectiveness studies assessing waning immunity using vaccinated and unvaccinated individuals are subject to biases. AimWe examined the association between time since vaccination and laboratory-confirmed influenza to assess the change in influenza vaccine protection over time. MethodsUsing linked laboratory and health administrative databases in Ontario, Canada, we identified community-dwelling individuals aged ≥ 6 months who received an influenza vaccine before being tested for influenza by RT-PCR during the 2010/11 to 2018/19 influenza seasons. We estimated the adjusted odds ratio (aOR) for laboratory-confirmed influenza by time since vaccination (categorised into intervals) and for every 28 days. ResultsThere were 53,065 individuals who were vaccinated before testing for influenza, with 10,264 (19%) influenza-positive cases. The odds of influenza increased from 1.05 (95% CI: 0.91–1.22) at 42–69 days after vaccination and peaked at 1.27 (95% CI: 1.04–1.55) at 126–153 days when compared with the reference interval (14–41 days). This corresponded to 1.09-times increased odds of influenza every 28 days (aOR = 1.09; 95% CI: 1.04–1.15). Individuals aged 18–64 years showed the greatest decline in protection against influenza A(H1N1) (aORper 28 days = 1.26; 95% CI: 0.97–1.64), whereas for individuals aged ≥ 65 years, it was against influenza A(H3N2) (aORper 28 days = 1.20; 95% CI: 1.08–1.33). We did not observe evidence of waning vaccine protection for individuals aged
Læs mere
29
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024
Marine Maurel, Jennifer Howard, Esther Kissling, Francisco Pozo, Gloria Pérez-Gimeno, Silke Buda, Noémie Sève, Adele McKenna, Adam Meijer, Ana Paula Rodrigues, Iván Martínez-Baz, Ivan Mlinarić, Neus Latorre-Margalef, Gergő Túri, Mihaela Lazăr, Clara Mazagatos, Aitziber Echeverria, Stephen Abela, Marc Bourgeois, Ausenda Machado, Ralf Dürrwald, Goranka Petrović, Beatrix Oroszi, Ligita Jancoriene, Alexandru Marin, Petr Husa, Roisin Duffy, Frederika Dijkstra, Virtudes Gallardo García, Luise Goerlitz, Vincent Enouf, Charlene Bennett, Mariëtte Hooiveld, Raquel Guiomar, Camino Trobajo-Sanmartín, Vesna Višekruna Vučina, Tove Samuelsson Hagey, Ana Sofía Lameiras Azevedo, Jesús Castilla, Gerd Xuereb, Bénédicte Delaere, Verónica Gómez, Kristin Tolksdorf, Sabrina Bacci, Nathalie Nicolay, Marlena Kaczmarek, Angela MC Rose and on behalf of the European IVE group
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: −3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: −32 to 43), respectively.
Læs mere
30
Communicable disease threats report, 11-17 February 2024, week 7
ECDC
ECDC Communicable Disease Threats Report, 16.02.2024
Tilføjet 16.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 11-17 February 2024, and includes updates on SARS-CoV-2 variant classification, diphtheria, chikungunya, dengue, influenza A(H5N1), a human case of co-infection with seasonal influenza A(H3N2) and avian influenza A(H10N5), Middle East respiratory syndrome coronavirus (MERS-CoV), and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
31
Communicable disease threats report, 11-17 February 2024, week 7
ECDC
ECDC COVID-19 updates, 16.02.2024
Tilføjet 16.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 11-17 February 2024, and includes updates on SARS-CoV-2 variant classification, diphtheria, chikungunya, dengue, influenza A(H5N1), a human case of co-infection with seasonal influenza A(H3N2) and avian influenza A(H10N5), Middle East respiratory syndrome coronavirus (MERS-CoV), and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
32
2023/24 mid-season influenza and Omicron XBB.1.5 vaccine effectiveness estimates from the Canadian Sentinel Practitioner Surveillance Network (SPSN)
Danuta M Skowronski, Yuping Zhan, Samantha E Kaweski, Suzana Sabaiduc, Ayisha Khalid, Romy Olsha, Sara Carazo, James A Dickinson, Richard G Mather, Hugues Charest, Agatha N Jassem, Inès Levade, Maan Hasso, Nathan Zelyas, Ruimin Gao and Nathalie Bastien
Eurosurveillance latest updates, 16.02.2024
Tilføjet 16.02.2024
The Canadian Sentinel Practitioner Surveillance Network reports mid-season 2023/24 influenza vaccine effectiveness (VE) of 63% (95% CI: 51–72) against influenza A(H1N1)pdm09, lower for clade 5a.2a.1 (56%; 95% CI: 33–71) than clade 5a.2a (67%; 95% CI: 48–80), and lowest against influenza A(H3N2) (40%; 95% CI: 5–61). The Omicron XBB.1.5 vaccine protected comparably well, with VE of 47% (95% CI: 21–65) against medically attended COVID-19, higher among people reporting a prior confirmed SARS-CoV-2 infection at 67% (95% CI: 28–85).
Læs mere
33
Laboratory Support for influenza and SARS-CoV-2 for Europe: AURORAE
ECDC
ECDC COVID-19 updates, 15.02.2024
Tilføjet 15.02.2024
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
Læs mere
34
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC Communicable Disease Threats Report, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
35
Communicable disease threats report, 4-10 February 2024, week 6
ECDC
ECDC COVID-19 updates, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mere
36
Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with Severe Acute Respiratory Infection, laboratory-confirmed with SARS-CoV-2 or with seasonal influenza - Version 3.0
ECDC
ECDC COVID-19 updates, 6.02.2024
Tilføjet 6.02.2024
This core protocol for ECDC studies of VE against hospitalisation with SARI laboratory-confirmed with SARS-CoV-2 or with influenza, version 3.0, represents an update to the main elements for a multi-country hospital-based study of COVID-19 vaccine effectiveness in patients hospitalised with SARI, initially published as version 1.0 [5], updated to version 2.0 [6].
Læs mere
37
Communicable disease threats report, 31 December 2023 - 6 January 2024, week 1
ECDC
ECDC Communicable Disease Threats Report, 5.02.2024
Tilføjet 5.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 December 2023-6 January 2024 and includes updates on Avian influenza A(H5N6 and H9N2), SARS-CoV-2 variant classification, Western Equine Encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
38
Communicable disease threats report, 31 December 2023 - 6 January 2024, week 1
ECDC
ECDC COVID-19 updates, 5.02.2024
Tilføjet 5.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31 December 2023-6 January 2024 and includes updates on Avian influenza A(H5N6 and H9N2), SARS-CoV-2 variant classification, Western Equine Encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
39
Communicable disease threats report, 28 January - 3 February 2024, week 5
ECDC
ECDC Communicable Disease Threats Report, 3.02.2024
Tilføjet 3.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
40
Communicable disease threats report, 28 January - 3 February 2024, week 5
ECDC
ECDC COVID-19 updates, 2.02.2024
Tilføjet 2.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 28 January - 3 February 2024 and includes updates on SARS-CoV-2 variant classification, swine influenza, human cases of co-infection with seasonal influenza and avian influenza, influenza, western equine encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere
41
Respiratory Virus Surge: Diagnosing COVID-19 vs RSV, Flu
Medscape Infectious Diseases, 1.02.2024
Tilføjet 1.02.2024
Amid the current winter wave surge of respiratory virus cases, how challenging is it for physician\'s to distinguish between, diagnose, and treat COVID-19 vs RSV and influenza? Medscape Medical News
Læs mere
42
Communicable disease threats report, 21-27 January 2024, week 4
ECDC
ECDC Communicable Disease Threats Report, 27.01.2024
Tilføjet 27.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
Læs mere
43
Communicable disease threats report, 21-27 January 2024, week 4
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 21-27 January 2024 and includes updates on SARS-CoV-2, influenza, cholera, chikungunya, dengue and zika.
Læs mere
44
Age-dependent influenza infection patterns and subtype circulation in Denmark, in seasons 2015/16 to 2021/22
Hanne-Dorthe Emborg, Amanda Bolt Botnen, Jens Nielsen, Lasse S. Vestergaard, Frederikke Kristensen Lomholt, Charlotte Munkstrup, Karina Lauenborg Møller, Charlotte Kjelsø, Steen Hulthin Rasmussen and Ramona Trebbien
Eurosurveillance latest updates, 26.01.2024
Tilføjet 26.01.2024
BackgroundInfluenza was almost absent for 2 years following the implementation of strict public health measures to prevent the spread of SARS-CoV-2. The consequence of this on infections in different age groups is not yet known. AimTo describe the age groups infected with the influenza virus in 2021/22, the first post-pandemic influenza season in Denmark, compared with the previous six seasons, and subtypes circulating therein. MethodsInfection and hospitalisation incidences per season and age group were estimated from data in Danish registries. Influenza virus subtypes and lineages were available from samples sent to the National Influenza Centre at Statens Serum Institut. ResultsTest incidence followed a similar pattern in all seasons, being highest in 0–1-year-olds and individuals over 75 years, and lowest in 7–14-year-olds and young people 15 years to late twenties. When the influenza A virus subtypes A(H3N2) and A(H1N1)pdm09 co-circulated in seasons 2015/16 and 2017/18 to 2019/20, the proportion of A(H1N1)pdm09 was higher in 0–1-year-olds and lower in the over 85-year-olds compared with the overall proportion of A(H1N1)pdm09 in these seasons. The proportion of A(H3N2) was higher in the over 85 years age group compared with the overall proportion of A(H3N2). The 2016/17 and 2021/22 seasons were dominated by A(H3N2) but differed in age-specific trends, with the over 85 years age group initiating the 2016/17 season, while the 2021/22 season was initiated by the 15–25-year-olds, followed by 7–14-year-olds. ConclusionThe 2021/22 influenza season had a different age distribution compared with pre-COVID-19 pandemic seasons.
Læs mere
45
Communicable disease threats report, 14-20 January 2024, week 3
ECDC
ECDC Communicable Disease Threats Report, 20.01.2024
Tilføjet 20.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 January 2024 and includes updates on avian influenza, SARS-CoV-2 variant classification, an overview of respiratory viruses in the EU/EEA, mpox, measles, and Infant formula for medical purposes recalled due to possible contamination with Cronobacter sakazakii.
Læs mere
46
Communicable disease threats report, 14-20 January 2024, week 3
ECDC
ECDC COVID-19 updates, 19.01.2024
Tilføjet 19.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 January 2024 and includes updates on avian influenza, SARS-CoV-2 variant classification, an overview of respiratory viruses in the EU/EEA, mpox, measles, and Infant formula for medical purposes recalled due to possible contamination with Cronobacter sakazakii.
Læs mere
47
A case of swine influenza A(H1N2)v in England, November 2023
Jade Cogdale, Beatrix Kele, Richard Myers, Ruth Harvey, Abi Lofts, Tanya Mikaiel, Katja Hoschler, Ashley C Banyard, Joe James, Benjamin C Mollett, Alexander MP Byrne, Jamie Lopez-Bernal, Conall H Watson, Meera Chand, William Welfare, Deborah A Williamson, Isabel Oliver, Simon Padfield, Andrew Lee, Suzanne Calvert, Martin A Bewley, Louise Wallace, Simon deLusignan, Nicola S Lewis, Ian H Brown, Maria Zambon and on behalf of the Influenza A(H1N2)v Incident Management Team
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
Under International Health Regulations from 2005, a human infection caused by a novel influenza A virus variant is considered an event that has potential for high public health impact and is immediately notifiable to the World Health Organisation. We here describe the clinical, epidemiological and virological features of a confirmed human case of swine influenza A(H1N2)v in England detected through community respiratory virus surveillance. Swabbing and contact tracing helped refine public health risk assessment, following this unusual and unexpected finding.
Læs mere
48
RespiCast: the new European Respiratory Diseases Forecasting Hub
ECDC
ECDC COVID-19 updates, 15.01.2024
Tilføjet 15.01.2024
The European Respiratory Diseases Forecasting Hub (RespiCast) is open for weekly submission of several respiratory disease indicators such as influenza-like-illness, acute respiratory infection and COVID-19.
Læs mere
49
Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season
Christa Smolarchuk, Carla Ickert, Nathan Zelyas, Jeffrey C Kwong and Sarah A Buchan
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58–64) against influenza A(H1N1), 49% (95% CI: 28–63) against influenza A(H3N2) and 75% (95% CI: 58–85) against influenza B.
Læs mere
50
Communicable disease threats report, 31-6 January 2024, week 1
ECDC
ECDC COVID-19 updates, 6.01.2024
Tilføjet 6.01.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 31-6 January 2024 and includes updates on Avian influenza A(H5N6 and H9N2), SARS-CoV-2 variant classification, Western Equine Encephalitis, and an overview of respiratory virus epidemiology in the EU/EEA.
Læs mere